Chengwen Li

Co-Founder, Director, AAV Platform Technology Programs at Bedrock Therapeutics

Chengwen Li is an Associate Professor of Pediatrics with a large, well funded lab in the Gene Therapy Center at UNC-Chapel Hill. He got his MD/PhD degree from Peking Union Medical School and completed his post-doc in Jude Samulski’s lab where him and Matt became friends and collaborators. Dr. Li’s research has defined basics aspects of the various host immune responses to AAV vectors while focusing on rare disease gene therapy, especially for hemophilia. Chengwen has published over 80 AAV-related manuscripts in peer-reviewed journals.